AOD 9604 research gives us a reason to be selective.
The mouse findings were interesting. The human weight-loss result was disappointing. Both deserve a plain sentence.
Curiosity doesn't require a yes.
The human result changes the story
AOD-9604's design borrows a small fragment from growth hormone. Researchers hoped that fragment would affect fat without bringing all the full hormone's effects with it. We can see why the idea drew interest.
Early experiments in obese mice explored changes in weight and fat metabolism. They helped researchers ask how the compound might work. They couldn't tell us whether it would help people lose weight.
In the human obesity trial, weight loss wasn't significantly greater than with placebo, the comparison without an active ingredient. Development for obesity stopped. We'd keep that disappointment visible whenever AOD-9604 is presented as a weight-loss option.
In the human safety and tolerability report, tolerability resembled the placebo group's experience. In everyday terms, people generally tolerated the treatment. That doesn't mean it delivered the hoped-for weight loss.
We're comfortable keeping both findings. A treatment can be tolerable in a trial and still fail to show the benefit it was designed for. The encouraging animal work doesn't cancel the disappointing human result.
The safety gaps still matter
No use of AOD-9604 has received FDA approval. The human studies don't give us a long-term safety picture. Rare harms are another question a limited trial record can't settle.
The FDA raises immune-reaction and peptide-impurity concerns. The FDA dates that page's content to April 22, 2026. In that version, AOD-9604's compounding request appears as withdrawn by the groups that submitted it.
Taking a request back isn't permission to compound. Category 1 status doesn't follow from a withdrawal. FDA still prints its safety concerns alongside the entry.
When the claim asks for too much
If the pitch is reliable human weight loss, these findings don't support it. We don't need to rule out every future research question to decline that claim now.
Adding another peptide doesn't fill the evidence gap. Nothing here establishes a safe, useful combination for a particular reader.
An interesting idea can remain an idea
There's no need to turn every experiment into something to try. The comparison page puts AOD-9604 beside semaglutide's human results and tesamorelin's different purpose.
If you read the original sources, keep two questions apart: did people tolerate it, and did it help with the intended goal? One answer can't stand in for the other.